[HTML][HTML] Graft-versus-host disease: how to translate new insights into new therapeutic strategies
MP Devetten, JM Vose - Biology of Blood and Marrow Transplantation, 2004 - Elsevier
Graft-versus-host disease occurs when transplanted donor-derived T lymphocytes recognize
major or minor histocompatibility complex proteins and their associated peptides expressed …
major or minor histocompatibility complex proteins and their associated peptides expressed …
Prophylaxis of acute GVHD: manipulate the graft or the environment?
AJ Barrett, K Le Blanc - Best Practice & Research Clinical Haematology, 2008 - Elsevier
Graft-versus-host disease (GVHD) is the immune response of donor T lymphocytes
responding to the recipient's alloantigens. The cellular and cytokine mechanisms driving …
responding to the recipient's alloantigens. The cellular and cytokine mechanisms driving …
Recent advances in the treatment of graft-versus-host disease
T Iwasaki - Clinical medicine & research, 2004 - Marshfield Clinic
Graft-versus-host disease (GVHD) is a lethal complication of allogeneic hematopoietic stem
cell transplantation (HSCT) where immunocompetent donor T cells attack the genetically …
cell transplantation (HSCT) where immunocompetent donor T cells attack the genetically …
Current and future approaches for control of graft-versus-host disease
J Koreth, JH Antin - Expert review of hematology, 2008 - Taylor & Francis
Graft-versus-host disease (GVHD), both acute and chronic, remains one of the major
barriers to improving outcomes after allogeneic stem cell transplantation. The …
barriers to improving outcomes after allogeneic stem cell transplantation. The …
New advances in acute graft‐versus‐host disease prophylaxis
JK Davies, MW Lowdell - Transfusion Medicine, 2003 - Wiley Online Library
Immunocompetent donor T cells in Allogeneic Haematopoietic Stem Cell grafts mediate
acute Graft versus Host Disease (GvHD), still a major cause of recipient morbidity and …
acute Graft versus Host Disease (GvHD), still a major cause of recipient morbidity and …
Pathophysiology of acute graft-versus-host disease: recent advances
Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially curative therapy
for many malignant and nonmalignant hematologic diseases. Donor T cells from the …
for many malignant and nonmalignant hematologic diseases. Donor T cells from the …
[HTML][HTML] Graft-versus-host disease: state of the science
AM Alousi, J Bolaños-Meade, SJ Lee - Biology of Blood and Marrow …, 2013 - Elsevier
Despite concerted research efforts, prevention and treatment of graft-versus-host disease
(GVHD) have not changed significantly over the past 3 decades. The goal of this session is …
(GVHD) have not changed significantly over the past 3 decades. The goal of this session is …
[HTML][HTML] Translational and clinical advances in acute graft-versus-host disease
M Gooptu, J Koreth - Haematologica, 2020 - ncbi.nlm.nih.gov
Acute graft-versus-host disease (aGvHD) is induced by immunocompetent alloreactive T
lymphocytes in the donor graft responding to polymorphic and non-polymorphic host …
lymphocytes in the donor graft responding to polymorphic and non-polymorphic host …
Pathogenesis and prevention of graft-versus-host disease
T Teshima, JLM Ferrara - Current Opinion in Organ …, 2001 - journals.lww.com
Graft-versus-host disease (GVHD) has been the primary limitation to the wider application of
allogeneic bone marrow transplantation. GVHD occurs when donor T cells react to host …
allogeneic bone marrow transplantation. GVHD occurs when donor T cells react to host …
Understanding the alloresponse: new approaches to graft-versus-host disease prevention
T Teshima, JLM Ferrara - Seminars in hematology, 2002 - Elsevier
Graft-versus-host disease (GVHD) has been the primary limitation to the wider application of
allogeneic bone marrow transplantation (BMT). GVHD occurs when donor T cells react to …
allogeneic bone marrow transplantation (BMT). GVHD occurs when donor T cells react to …